Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Anita Ahmed Turk"'
Publikováno v:
Journal of Clinical Oncology. 41:731-731
731 Background: The incidence of PDAC is on the rise and it is predicted to be the 2nd leading cause of cancer related mortality in the next decade. Most patients present with advanced disease at diagnoses with limited systemic treatment options. Flu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbcfddb638335ada6977e98f2e12666e
https://doi.org/10.1200/jco.2023.41.4_suppl.731
https://doi.org/10.1200/jco.2023.41.4_suppl.731
Autor:
Ahmad Al-Hader, Ekin Secinti, Victoria L. Champion, Paul R. Helft, Shelley A. Johns, Catherine E. Mosher, Patrick J. Loehrer, Anita Ahmed Turk, Kurt Kroenke, Amikar Sehdev
Publikováno v:
Pilot and Feasibility Studies
Pilot and Feasibility Studies, Vol 7, Iss 1, Pp 1-12 (2021)
Pilot and Feasibility Studies, Vol 7, Iss 1, Pp 1-12 (2021)
Background Fatigue interference with activities, mood, and cognition is one of the most prevalent and bothersome concerns of advanced gastrointestinal (GI) cancer patients. As fatigue interferes with patient functioning, family caregivers often repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a632dcab9d2c7a3fb8b684c820d0cdd8
http://europepmc.org/articles/PMC8056101
http://europepmc.org/articles/PMC8056101
Autor:
Sherise C. Rogers, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Anita Ahmed Turk, Karen Bullock Russell, Ibrahim Nassour, Ahmad El-Far, Jesus C. Fabregas, Ryan M. Thomas, Ilyas Sahin, Carmen Joseph Allegra, David L. DeRemer, Thomas J. George
Publikováno v:
Journal of Clinical Oncology. 40:TPS4196-TPS4196
TPS4196 Background: Neoadjuvant treatment for potentially curable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4412e3143f5f62b5ab0d803426aeae4f
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4196
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4196
Autor:
Sherise C. Rogers, Ilyas Sahin, Jesus C. Fabregas, Ibrahim Nassour, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Omar Roger Kayaleh, Anita Ahmed Turk, Z. Hugh Fan, Karen Bullock Russell, David L. DeRemer, Thomas J. George
Publikováno v:
Journal of Clinical Oncology. 40:TPS619-TPS619
TPS778 Background: Neoadjuvant treatment for potentially curable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFIR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46985529211bd08b7bde1e7b7a46fb6a
https://doi.org/10.1200/jco.2022.40.4_suppl.tps619
https://doi.org/10.1200/jco.2022.40.4_suppl.tps619
Autor:
Kristen Renee Spencer, Anita Ahmed Turk, Shikha Jain, Kelsey Klute, Sam Joseph Lubner, Dirk F. Moore, Howard S. Hochster
Publikováno v:
Journal of Clinical Oncology. 40:TPS493-TPS493
TPS493 Background: Both the incidence and death rate of hepatocellular carcinoma (HCC) are on the rise in the United States, and overall, the prognosis is grim. First-line treatment options for patients with advanced disease previously included tyros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e9aceb063278713a2398d24b91b0f00
https://doi.org/10.1200/jco.2022.40.4_suppl.tps493
https://doi.org/10.1200/jco.2022.40.4_suppl.tps493
Autor:
Anita Ahmed Turk, Kari B. Wisinski
Publikováno v:
Cancer. 124:2498-2506
Individuals with breast and ovarian cancer susceptibility gene 1 (BRCA1) or BRCA2 germline mutations have a significantly increased lifetime risk for breast and ovarian cancers. BRCA-mutant cancer cells have abnormal homologous recombination (HR) rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d86aebb017a6fef84851167811213609
https://doi.org/10.1002/cncr.31307
https://doi.org/10.1002/cncr.31307
Autor:
Sherise C. Rogers, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Z. Hugh Fan, Carmen Joseph Allegra, Jose Trevino, Ahmad El-Far, Anita Ahmed Turk, Karen Bullock Russell, David L. DeRemer, Thomas J. George
Publikováno v:
Journal of Clinical Oncology. 39:TPS4170-TPS4170
TPS4170 Background: Neoadjuvant treatment for potentially curable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9abe248ffcd9020ecd64d7851c3601f2
https://doi.org/10.1200/jco.2021.39.15_suppl.tps4170
https://doi.org/10.1200/jco.2021.39.15_suppl.tps4170
Autor:
Jose G. Trevino, Ahmad El-Far, David L. DeRemer, Anita Ahmed Turk, Carmen J. Allegra, Sherise C. Rogers, Kathryn E. Hitchcock, Z. Hugh Fan, Thomas J. George, Steven J. Hughes, Ji-Hyun Lee, Brian Hemendra Ramnaraign, Karen Bullock Russell
Publikováno v:
Journal of Clinical Oncology. 39:TPS446-TPS446
TPS446 Background: Neoadjuvant treatment for potentially curable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFIR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ed207df184fb34502deaec25c23815a
https://doi.org/10.1200/jco.2021.39.3_suppl.tps446
https://doi.org/10.1200/jco.2021.39.3_suppl.tps446
Autor:
Filip Janku, James J. Harding, Masafumi Ikeda, Rebecca Tupper, Matthew P. Hanley, Mary Linton B. Peters, James Michael Pauff, Carrie E. Furin, Kurt A. Jaeckle, Rachna T. Shroff, Elizabeth G. Hill, Toshio Shimizu, Lipika Goyal, James M. Cleary, Nilofer S. Azad, Anita Ahmed Turk, Xiaojian Xu, Mitesh J. Borad, Kyriakos P. Papadopoulos, Sani H. Kizilbash
Publikováno v:
Journal of Clinical Oncology. 39:TPS350-TPS350
TPS350 Background: Mutations in isocitrate dehydrogenase 1 (mIDH1) are found in approximately 20-30% of patients with intrahepatic cholangiocarcinoma (CCA), and less commonly in glioma, chondrosarcoma, and other gastrointestinal malignancies. Despite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb16607db9e7d9bc440e3cea8875aabb
https://doi.org/10.1200/jco.2021.39.3_suppl.tps350
https://doi.org/10.1200/jco.2021.39.3_suppl.tps350
Autor:
Jason M. Norman, Bruce L. Roberts, Judy Wang, Diwakar Davar, Michael Cecchini, Zev A. Wainberg, Bernat Olle, Anita Ahmed Turk, Dmitri Bobilev, Rose L. Szabady, Martin Gutierrez
Publikováno v:
Cancer Research. 80:CT246-CT246
Background: Gut microbiome composition affects response to PD-1 blockade; and recent proof of concept studies suggest that gut microbiome manipulation is effective in reversing resistance to PD-1 blockade. VE800 is an oral live biotherapeutic consist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0dd8c421835f203e8db75a18fab25ffe
https://doi.org/10.1158/1538-7445.am2020-ct246
https://doi.org/10.1158/1538-7445.am2020-ct246